Thrombin generation, inhibition and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: Results from the GUSTO-I trial

Journal of the American College of Cardiology

Volumn 31, Issue 3, 1998, Pages 497-505

  Granger, Christopher B ^a   Becker, Richard ^b   Tracy, Russell P ^c   Califf, Robert M ^a   Topol, Eric J ^d   Pieper, Karen S ^a   Ross, Allan M ^e   Roth, Sherryn ^f   Lambrew, Costas ^g   Bovill, Edwin G ^c  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF VERMONT   (United States)

^e GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^f SCARBOROUGH HOSPITAL   (Canada)

^g MAINE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; HEPARIN; THROMBIN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; FEMALE; FIBRINOGENOLYSIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN DEGRADATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; ANTITHROMBIN III; CONFOUNDING FACTORS (EPIDEMIOLOGY); FEMALE; FIBRINOLYTIC AGENTS; FIBRINOPEPTIDE A; HEPARIN; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PEPTIDE HYDROLASES; STREPTOKINASE; THROMBIN; THROMBOLYTIC THERAPY; THROMBOSIS; TREATMENT OUTCOME;

EID: 0032031688     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(97)00539-1     Document Type: Article

References (21)

1. Eisenberg PR, Sherman LA, Jaffe AS. Paradoxic elevation of fibrinopeptide A after streptokinase evidence of continued thrombosis despite intense fibrinolysis . J Am Coll Cardiol. 10:1987;527-529.
2. Eisenberg PR, Sherman LA, Rich M, et al. Importance of continued activation of thrombin reflected by fibrinopeptide A to the efficacy of thrombolysis. J Am Coll Cardiol. 7:1986;1255-1262.
3. Rapold HJ, Kuemmerli H, Weiss M, Baur H, Haeberli A. Monitoring of fibrin generation during thrombolytic therapy of acute myocardial infarction with recombinant tissue-type plasminogen activator. Circulation. 79:1989;980-989.
4. Rapold HJ, de Bono D, Arnold AER, et al., for the European Cooperative Study Group. Plasma fibrinopeptide A levels in patients with acute myocardial infarction treated with alteplase: correlation with concomitant heparin, coronary artery patency, and recurrent ischemia. Circulation 1992;85:928-34.
5. Hsia J, Kleiman NS, Aguirre FV, Chaitman BR, Roberts R, Ross AM. Heparin-induced prolongation of partial thromboplastin time after thrombolysis relation to coronary artery patency . J Am Coll Cardiol. 20:1992;31-35.
6. Arnout J, Simoons M, de Bono D, Rapold HJ, Collen D, Verstraete M. Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (t-PA). J Am Coll Cardiol. 20:1992;513-519.
7. Hirsh J. Heparin. N Engl J Med. 324:1991;1565-1574.
8. Gulba DC, Barthels M, Westhoff-Bleck M, et al. Increased thrombin levels during thrombolytic therapy in acute myocardial infarction relevance for the success of therapy . Circulation. 83:1991;937-944.
9. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 329:1993;673-682.
10. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med. 329:1993;1615-1622.
11. Lawler CM, Bovill EG, Stump DC, Collen DJ, Mann KG, Tracy RP. Fibrin fragment D-dimer and fibrinogen B beta peptides in plasma as markers of clot lysis during thrombolytic therapy in acute myocardial infarction. Blood. 76:1990;1341-1348.
12. Lidon RM, Theroux P, Juneau M, Adelman B, Maraganore J. Initial experience with a direct antithrombin, Hirulog, in unstable angina anticoagulant, antithrombotic, and clinical effects . Circulation. 88:1993;1495-1501.
13. Galvani M, Abendschein DR, Ferrini D, Ottani F, Rusticali F, Eisenberg PR. Failure of fixed dose intravenous heparin to suppress increases in thrombin activity after coronary thrombolysis with streptokinase. J Am Coll Cardiol. 24:1994;1445-1452.
14. Merlini PA, Bauer KA, Oltrona L, et al. Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction. J Am Coll Cardiol. 25:1995;203-209.
15. Neuhaus KL, von Essen R, Tebbe U, et al. Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase results of the rt-PA-APSAC patency study . J Am Coll Cardiol. 19:1992;885-891.
16. Bovill EG, Terrin ML, Stump DC, et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction results of the Thrombolysis In Myocardial Infarction (TIMI), Phase II trial . Ann Intern Med. 115:1991;256-265.
17. Rao AK, Pratt C, Berke A, et al., for the TIMI investigators. Thrombolysis In Myocardial Infarction (TIMI) trial - Phase I: hemorrhagic manifestations and changes in plasma fibrinogen and fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988;11:1-11.
18. Gore JM, Granger CB, Sloan MA, et al., for the GUSTO Investigators. Stroke after thrombolysis: mortality and functional outcomes in the GUSTO-I trial. Circulation 1995;92:2811-8.
19. Berkowitz SD, Granger CB, Pieper KS, et al., for the GUSTO-I Investigators. Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. Circulation 1997;95:2508-16.
20. Lee KL, Woodlief LH, Topol EJ, et al., for the GUSTO-I Investigators. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction: results from an international trial of 41,021 patients. Circulation 1995;91:1659-68.
21. Sobel BE. Intracranial bleeding, fibrinolysis, and anticoagulation causal connections and clinical implications . Circulation. 90:1994;2147-2152.